A Agilent Technologies Inc.

Agilent Technologies Global Lab Manager Survey Reveals Key Insights

Agilent Technologies Inc. (NYSE: A) today announced that a recently commissioned global survey will help the company continue to focus more intently on the needs of its customers around the world.

The market research firm of Frost & Sullivan conducted the independent survey - Understanding Key Challenges and Pain Points in the Global Laboratory Market - on Agilent’s behalf. The primary objective of the survey, which included 700 laboratory employees in four countries, was to understand key customer concerns and identify any unmet needs, as well as the differences and similarities of the challenges lab managers face.

“The results were very informative,” said Lon Justice, vice president of sales, marketing and customer experience at Agilent.

Survey respondents from Asia, Europe and United States included experienced lab managers, performing a range of functions in laboratories large and small across the many market segments Agilent serves.

The survey centered on several main themes, including productivity, workflow optimization, lab size, and operational goals. Many respondents indicated that dealing with the challenges of sample prep, as well as unplanned and unexpected instrument downtime, remains a major problem, as well as the increasing complexity of the testing requirements and sustainability goals impacting their organizations.

“Agilent is dedicated to continually listening to our customers to ensure their success, and this survey positively underscores our customer-centric approach,” Justice said. “We consult with our customers regarding the development of new products, and endeavor to understand their goals and day-to-day pain points so that we remain a trusted partner.”

Lab managers were asked to rank their top five challenges which included instrument maintenance and downtime (73%), the growing complexities of instrument testing requirements (63%), time consuming sample preparation (60%). Keeping up-to-date with changing regulations (52%) and the need for better data management (50%) also ranked in the top 5.

40% of respondents revealed a need to optimize their workflow, indicating that the main strategic changes that could help would be improved productivity and throughput (51%), followed by streamlined processes to manage growing workloads (26%). In fact, 45% of lab managers reported that they face significant pressure to process more samples per week.

“A big challenge is the size of our lab, as we are growing and experiencing a higher volume of samples,” one respondent told Frost & Sullivan. Some respondents shared that they are managing this by outsourcing, but worry about compromised quality of results.

“Interestingly the survey told us that around one in five of lab managers (18%) consider lab size to be a challenge affecting their lab’s performance. Of those, 75% believe that space-saving designs of instruments could help overcome this issue,” Justice said. “The new Ultivo LC/triple quad mass spec system announced at this week´s ASMS conference, as well as the recent launch of the Agilent Intuvo GC system, are clear demonstrations of how Agilent is directly responding to our customers concerns,” he concluded.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), is a global leader in analytical laboratory technologies. With more than 50 years of insight and innovation, our instruments, software, services, solutions and people provide trusted answers to our customers’ most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.

EN
07/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch